|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 39/395 | |
| A61P 35/00 | |||
| G01N 33/574 | |||
| C07K 16/28 | |||
| C07K 16/30 |
| (11) | Number of the document | 3180025 |
| (13) | Kind of document | T |
| (96) | European patent application number | 15754347.1 |
| Date of filing the European patent application | 2015-08-11 | |
| (97) | Date of publication of the European application | 2017-06-21 |
| (45) | Date of publication and mention of the grant of the patent | 2020-02-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2015/044632 |
| Date | 2015-08-11 |
| (87) | Number | WO 2016/025464 |
| Date | 2016-02-18 |
| (30) | Number | Date | Country code |
| 201462037848 P | 2014-08-15 | US |
| (72) |
ABADA, Paolo Benjamin, US
CHANG, Shao-Chun, US
HSU, Yanzhi, US
YANG, Ling, US
|
| (73) |
Imclone, LLC,
Eli Lilly and Company Lilly Corporate Center, Indianapolis, Indiana 46285,
US
|
| (54) | ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA |
| ANTI-VEGFR2 ANTIBODY THERAPY FOR HEPATOCELLULAR CARCINOMA |